In vitro testing of nitric oxide-releasing microparticles shows efficacy against Trichophyton and Candida, suggesting a novel antifungal treatment.
Onychomycosis is one of the most prevalent fungal infections worldwide, resulting in negative effects on general quality of life. Management of the disease encounters a series of obstacles, and antifungal treatment has a low success rate. We aimed to develop and evaluate a novel formulation of NO-releasing microparticles (SNO-MPs) against some of the most common causative agents of onychomycosis: Trichophyton mentagrophytes, Trichophyton rubrum, Candida albicans, and Aspergillus flavus. SNO-MP susceptibility testing was performed in vitro, and MICs and MFCs were established for multiple strains. SNO-MP was also tested ex vivo in human nail fragments, with biofilm formation and biofilm disruption assessed using scanning electron microscopy and colony-forming unit counting. The particles demonstrated the ability to destroy biofilms formed by either Trichophyton sp. or C. albicans. SNO-MP was not effective against A. flavus, which appears to have a nitrosative resistance mechanism that has not yet been elucidated. Cytotoxicity was assessed against human dermal fibroblasts and keratinocytes. SNO-MP demonstrated a manageable degree of cytotoxicity when tested against human dermal fibroblasts and keratinocytes. Our findings highlight that SNO-MP represents a potentially potent alternative for the treatment of onychomycosis due to Trichophyton and Candida.
No takes yet. Share an insight, caveat, or question.
Valdez et al. (2025) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: